Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Figs Inc. (FIGS) Stock Forecast & Price Prediction United States | NYSE | Consumer Cyclical | Apparel Manufacturing
$16.06
+0.67 (4.35%)Did FIGS Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if FIGS is one of their latest high-conviction picks.
Based on our analysis of 16 Wall Street analysts, FIGS has a bullish consensus with a median price target of $17.00 (ranging from $14.00 to $22.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $16.06, the median forecast implies a 5.9% upside. This outlook is supported by 5 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brian Nagel at Oppenheimer, projecting a 37.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for FIGS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | Morgan Stanley | Lauren Schenk | Equal-Weight | Maintains | $15.00 |
| Mar 20, 2026 | Oppenheimer | Brian Nagel | Outperform | Upgrade | $22.00 |
| Mar 12, 2026 | Telsey Advisory Group | Dana Telsey | Market Perform | Maintains | $17.00 |
| Mar 4, 2026 | BTIG | Robert Drbul | Buy | Maintains | $20.00 |
| Feb 27, 2026 | Keybanc | Ashley Owens | Overweight | Upgrade | $17.00 |
| Feb 27, 2026 | Telsey Advisory Group | Dana Telsey | Market Perform | Maintains | $15.00 |
| Feb 27, 2026 | BTIG | Robert Drbul | Buy | Reiterates | $15.00 |
| Feb 20, 2026 | Telsey Advisory Group | Dana Telsey | Market Perform | Maintains | $9.00 |
| Jan 30, 2026 | Goldman Sachs | Brooke Roach | Sell | Maintains | $7.50 |
| Jan 13, 2026 | Morgan Stanley | Lauren Schenk | Equal-Weight | Maintains | $8.00 |
| Jan 6, 2026 | Barclays | Adrienne Yih | Equal-Weight | Maintains | $11.00 |
| Dec 10, 2025 | BTIG | Robert Drbul | Buy | Maintains | $15.00 |
| Nov 19, 2025 | Morgan Stanley | Lauren Schenk | Equal-Weight | Maintains | $7.50 |
| Nov 13, 2025 | BTIG | Robert Drbul | Buy | Maintains | $12.00 |
| Nov 10, 2025 | Barclays | Adrienne Yih | Equal-Weight | Maintains | $9.00 |
| Nov 7, 2025 | Goldman Sachs | Brooke Roach | Sell | Maintains | $5.50 |
| Nov 7, 2025 | BTIG | Robert Drbul | Buy | Maintains | $10.00 |
| Nov 7, 2025 | Telsey Advisory Group | Dana Telsey | Market Perform | Maintains | $9.00 |
| Nov 3, 2025 | Telsey Advisory Group | Dana Telsey | Market Perform | Maintains | $7.00 |
| Oct 15, 2025 | BTIG | Robert Drbul | Buy | Initiates | $9.00 |
The following stocks are similar to FIGS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Figs Inc. has a market capitalization of $2.67B with a P/E ratio of 81.0x. The company generates $631.10M in trailing twelve-month revenue with a 5.4% profit margin.
Revenue growth is +33.0% quarter-over-quarter, while maintaining an operating margin of +9.3% and return on equity of +8.4%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Designs and sells stylish medical scrubs.
The company operates a direct-to-consumer model primarily through e-commerce, allowing it to efficiently reach healthcare professionals seeking high-performance workwear. By focusing on innovative fabric technology and stylish design, it captures the growing demand for specialized medical apparel.
Figs Inc. is committed to sustainability and ethical manufacturing, actively participating in initiatives that support healthcare communities. Established in Los Angeles, the brand has successfully redefined medical uniforms, merging fashion with functionality and positioning itself as a leader in the niche market of medical apparel.
Consumer Cyclical
Apparel Manufacturing
330
Ms. Catherine Eva Spear
United States
2021
TSCO heads into Q1 earnings with revenues seen rising 4.9%, but weather swings, tariffs and rising costs may keep profit growth muted.
Figs (FIGS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bath & Body Works' international sales jump in Q4 as store expansion accelerates, signaling rising global demand and a capital-light path to long-term growth.
Figs (FIGS) has a strong earnings surprise history and is well-positioned for a potential beat in its upcoming quarterly report.
Figs' strong earnings surprise history and favorable conditions suggest potential for positive future earnings, which can drive stock price and investor confidence.
CVX, CRGY, LUMN, FIGS, and BCBP have been assigned a Zacks Rank #1 (Strong Buy) as of April 6, 2026.
Zacks Rank #1 indicates strong potential for these stocks, suggesting favorable earnings outlooks that could lead to price appreciation and attract investor interest.
FIGS, CVX, and EQX are rated as Zacks Rank #1 (Strong Buy) momentum stocks as of April 6, 2026.
Zacks Rank #1 indicates strong potential for growth in FIGS, CVX, and EQX, signaling favorable market conditions and investment opportunities for attractive returns.
Figs (FIGS) and Tilly's (TLYS) performance has been compared to their sector's performance for the year to date. Further details on specific metrics were not provided.
Performance comparisons signal relative strength or weakness, influencing investor sentiment and potential stock movements within the sector.
Figs (FIGS) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects, which may lead to higher stock performance.
Figs' upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock prices higher.
FIGS, KRT, and EFXT were added to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 23, 2026.
FIGS, KRT, and EFXT being ranked as Strong Buy indicates strong positive momentum and potential for price appreciation, signaling favorable investment opportunities.
Based on our analysis of 16 Wall Street analysts, Figs Inc. (FIGS) has a median price target of $17.00. The highest price target is $22.00 and the lowest is $14.00.
According to current analyst ratings, FIGS has 5 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.06. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict FIGS stock could reach $17.00 in the next 12 months. This represents a 5.9% increase from the current price of $16.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company operates a direct-to-consumer model primarily through e-commerce, allowing it to efficiently reach healthcare professionals seeking high-performance workwear. By focusing on innovative fabric technology and stylish design, it captures the growing demand for specialized medical apparel.
The highest price target for FIGS is $22.00 from Brian Nagel at Oppenheimer, which represents a 37.0% increase from the current price of $16.06.
The lowest price target for FIGS is $14.00 from at , which represents a -12.8% decrease from the current price of $16.06.
The overall analyst consensus for FIGS is bullish. Out of 16 Wall Street analysts, 5 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $17.00.
Stock price projections, including those for Figs Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.